Clinical effect of miconazole gel against upper digestive tract mycosis
Tsubura, E.; Noma, K.; Ikemoto, H.; Mori, T.; Mikuni, C.; Oizumi, K.; Kashiwabara, H.; Itoh, A.; Uchino, H.; Sawada, H.
Japanese Journal of Antibiotics 44(3): 324-336
1991
ISSN/ISBN: 0368-2781 PMID: 1880914 Document Number: 383190
A total of 43 patients, comprising 41 patients with oral candidiasis and 2 with esophageal candidiasis, were treated with miconazole (MCZ) gel to assess its efficacy and safety in treating upper digestive tract mycosis. The efficacy of the drug was evaluable in 33 of them, consisting of 32 patients with oral candidiasis and 1 with esophageal candidiasis. The clinical efficacy rate of the drug against oral candidiasis was 87.5% (28/32 patients), and the clinical response was good in the 1 evaluable patient with esophageal candidiasis. The safety of the drug was assessed in 40 patients. In 3 (7.5%) of them, nausea occurred as an adverse event, but was not particularly serious in any of them. No abnormal laboratory test values caused by the drug were observed. The results suggested that MCZ gel would be a very useful drug in treating oral and esophageal candidiasis.